Welcome to BioCAT

Science Highlights

Probing the Powering of Contractions in Heart Failure

Current treatments can slow progression of heart failure, but do not address the underlying issues, including specific problems that cause systolic heart failure. In this condition, the heart doesn’t contract vigorously enough in pushing blood into the body’s circulation. But findings at nanometer and millisecond scales, based upon experimental data collected at BioCAT may help improve design of therapies directed at motor proteins to rescue failing hearts.

Learn More

A Target Mutation that Renders a Cancer Drug Ineffective

Mutations in the gene PTPN11, which encodes a common enzyme called SHP2, can result in developmental disorders, such as Noonan Syndrome, and act as oncogenic drivers in patients with certain blood cancers. Due to the well understood role of the enzyme SHP2 in Noonan Syndrome and in tumorigenesis, many companies are currently trying to develop drugs that inhibit the enzyme. Researched investigated what impact mutations to SHP2 may have on the potential efficacy of drugs targeting this enzyme.

Learn More

Unraveling the role of a “nebulous” protein

Nebulin is a protein important to muscle strength, as mutations can cause the muscles in patients with nemaline myopathy disease to be weak, little is known about how it works. Researchers investigated the function of Nebulin in mice and found that it is necessary for generating physiological levels of force.

Learn More


Everything BioSAXS 5 workshop

BioCAT will run its 5th annual Everything BioSAXS workshop from November 5-7th. Registration is now closed for both on-site and, for the first time ever, remote participants.

Learn More

SAS2018 Advanced BioSAXS workshop a big success

BioCAT co-organized and ran an international advanced BioSAXS workshop at the SAS2018 meeting in October 2018.

Learn More

BioCAT user Joshua Riback wins Rosland Franklin Investigator Award

Joshua Riback, a BioCAT user in his fifth year of graduate studies at the University of Chicago, was recognized for his work using SEC-SAXS at BioCAT to study biophysical interactions.

Learn More